GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Asset Turnover

AbbVie (AbbVie) Asset Turnover : 0.11 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is AbbVie Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AbbVie's Revenue for the three months ended in Dec. 2023 was $14,301 Mil. AbbVie's Total Assets for the quarter that ended in Dec. 2023 was $135,466 Mil. Therefore, AbbVie's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.

Asset Turnover is linked to ROE % through Du Pont Formula. AbbVie's annualized ROE % for the quarter that ended in Dec. 2023 was 29.29%. It is also linked to ROA % through Du Pont Formula. AbbVie's annualized ROA % for the quarter that ended in Dec. 2023 was 2.43%.


AbbVie Asset Turnover Historical Data

The historical data trend for AbbVie's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Asset Turnover Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.38 0.38 0.41 0.40

AbbVie Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.09 0.10 0.10 0.11

Competitive Comparison of AbbVie's Asset Turnover

For the Drug Manufacturers - General subindustry, AbbVie's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Asset Turnover distribution charts can be found below:

* The bar in red indicates where AbbVie's Asset Turnover falls into.



AbbVie Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

AbbVie's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=54318/( (138805+134711)/ 2 )
=54318/136758
=0.40

AbbVie's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=14301/( (136221+134711)/ 2 )
=14301/135466
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


AbbVie  (NYSE:ABBV) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

AbbVie's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=3288/11227
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(3288 / 57204)*(57204 / 135466)*(135466/ 11227)
=Net Margin %*Asset Turnover*Equity Multiplier
=5.75 %*0.4223*12.0661
=ROA %*Equity Multiplier
=2.43 %*12.0661
=29.29 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

AbbVie's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=3288/135466
=(Net Income / Revenue)*(Revenue / Total Assets)
=(3288 / 57204)*(57204 / 135466)
=Net Margin %*Asset Turnover
=5.75 %*0.4223
=2.43 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


AbbVie Asset Turnover Related Terms

Thank you for viewing the detailed overview of AbbVie's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (AbbVie) Business Description

Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Executives
Nicholas Donoghoe officer: SVP, Enterprise Innovation 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin director 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis director 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez officer: Chairman of the Board and CEO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg officer: Sr. V.P., U.S. Commercial Ops. 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis officer: EVP, GC and Secretary 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart officer: SVP, US Commercial Operations 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee officer: SVP, Controller 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents officer: SVP, Chief Financial Officer 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt officer: SVP, Operations 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom officer: SVP & Pres Global Allerg Aesth 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin director 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond officer: EVP, Chief HR Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino officer: EVP, R&D and CSO 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch officer: Chief Strategy Officer 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092

AbbVie (AbbVie) Headlines